State of 3D Printing, Bioprinting and Investment, Q4 2026
3D printing is a $24 billion industry growing about 11% a year, capital is flowing to fewer, larger production-scale bets in defense and metal, and bioprinting is still pre-commercial except for drug-testing tissue models.
Market size: the real number is about $24 billion
The most cited benchmark, the Wohlers Report 2026, puts global additive manufacturing revenue at $24.2 billion in 2025, up 10.9% year on year. That is a slight uptick from 2024 but well below the 20%-plus growth rates seen before the pandemic.
The mix matters more than the headline. Wohlers reports AM services grew 15.5% in 2025 while system (printer) sales grew only 3.6%. Customers are buying parts and running the machines they already own harder, rather than buying many new machines. Wohlers also reports defense is now the leading revenue-generating sector, followed by aerospace, medical and research.
Other analyst firms publish far larger figures because they define the market more broadly (hardware, materials, software, services, and sometimes adjacent categories) and then apply 17% to 24% growth rates. Treat these as scope differences, not disagreement about reality.
| Source | 2026 estimate (USD) | Stated growth |
|---|---|---|
| Wohlers Associates (2025 actual) | $24.2B | 10.9% in 2025 |
| Fortune Business Insights | $28.6B | 21.6% CAGR to 2034 |
| Coherent Market Insights | $31.5B | 24.0% CAGR to 2033 |
| Precedence Research | $34.9B | 18.5% CAGR to 2034 |
| Knowledge Sourcing | $58.1B | not stated in excerpt |
| Research Nester | $137.3B | 21.4% CAGR to 2035 |
For planning or investor material, anchor on the Wohlers figure and quote the others only as a range of forecasts. A fair reading is that growth has settled in the low-to-mid teens at best, with metal, defense and services growing faster than desktop and polymer hardware.
Investment: fewer deals, bigger checks, production-scale companies
Tracxn counts $403 million raised across 17 equity rounds in the first half of 2026, against $470 million across 29 rounds in the first half of 2025. That is about 14% less capital and 41% fewer rounds, so the average round grew from roughly $16 million to roughly $24 million. Tracxn’s category boundaries are narrower than the deals below (it will not capture every defense-manufacturing round), but the direction matches what 3DPrint.com describes: investors backing fewer companies with bigger checks, for businesses already delivering production at scale.
| When | Company | Round | Amount | Who and why |
|---|---|---|---|---|
| Oct 14, 2026 | Icon | Series D | $200M | Co-led by Baillie Gifford with funds managed by BlackRock; funds Titan printer production and an R&D site in Austin |
| Sep 2026 | Impossible Objects | Series B | $40M | Led by Inflection Equity; composite parts for aerospace and defense |
| Late Aug 2026 | Hike Medical | Seed and Series A | $22.5M | Led by Saga Ventures; custom medical devices from a 600-printer farm |
| Mid 2026 | Math Magic | Two rounds | nearly $50M | BAI Capital and HyT Capital; AI 3D generation plus production and delivery |
| Jan 2026 | VulcanForms | Series D | $220M | Led by Eclipse and 1789 Capital; customer demand exceeded capacity for the first time |
| Sep 2025 | Divergent | Series E | $290M ($250M equity, $40M debt) | Led by Rochefort at a $2.3B valuation; aerospace and defense customers |
| May 29, 2026 | Creality | Hong Kong IPO | HK$1.272B | First consumer 3D printing company on the HKEX main board (ticker 3388) |
One caution: a pre-IPO tracker, DefiLlama, lists a further $225 million Divergent round in July 2026 at a $3.37 billion valuation. I could not confirm that against a company or press source, so treat it as unverified.
Dedicated specialist funds are still small. AM Ventures, the Langer Group’s venture arm in Munich, closed a hard-capped fund of about EUR 100 million and holds roughly 17 seed-stage companies across hardware, software, materials and applications. The Stifel North Atlantic AM-Forward Fund put $10 million into aerospace AM service provider Sintavia. Early-stage activity continues at small sizes, for example Radian Forge ($2.5 million seed for large maritime and defense metal components) and Unlayered 3D, both in the same September roundup.
What the money is buying, in order of size: (1) metal and composite production capacity for defense and aerospace, (2) robotic construction printing, (3) medical device manufacturing at scale, (4) AI design and software layers. Pure printer-hardware startups selling to labs are the segment getting least attention.
Public companies and consolidation: the roll-up thesis failed
The two largest Western polymer and mixed-technology players are roughly flat on revenue and near break-even. Both are leaning on recurring revenue and on healthcare or aerospace and defense, not on new printer sales.
| Company (Q2 2026, quarter ended June 30) | Revenue | What moved | Profitability and cash |
|---|---|---|---|
| Stratasys | $137.6M (flat vs $138.1M) | Record consumables of $66.3M; aerospace and defense up 17%; system sales down to $26.4M from $30.6M | GAAP net loss $16.9M; adjusted EBITDA $5.3M; $212.5M cash, no debt; 2026 revenue guidance $565M to $575M |
| 3D Systems | $94.6M (down 0.3%; up 1.4% excluding 2025 software divestitures) | Healthcare up 6.8% to $48.1M; Industrial down 6.7% to $46.5M; printer sales up more than 45% | Adjusted EBITDA of negative $0.8M; $129M cash after a $53.2M equity raise; Q3 guidance $96M to $99M |
Sources for the Stratasys operating detail beyond the press release: MarketBeat’s call summary. For 3D Systems: call details.
The larger story is how the 2023 to 2026 consolidation attempt unwound.
| Date | Event |
|---|---|
| 2023 | Nano Dimension makes unsolicited bids for Stratasys; they stall (3D Printing Industry) |
| Apr 2, 2025 | Nano Dimension closes its $179.3M Desktop Metal acquisition after a Delaware court compelled it to complete the deal (AM Insight Asia) |
| Apr 25, 2025 | Nano closes Markforged, originally bought for about $116M |
| Jul 28, 2025 | Desktop Metal files for Chapter 11, 117 days after the deal closed; foreign subsidiaries go to an affiliate of Anzu Partners |
| FY2025 | Nano books $139.4M of Desktop Metal impairment losses; cash at year end is about $460M |
| May 27, 2026 | Nano agrees to sell Markforged to Stratasys for $42.5M cash, keeping the Metal Binder Jetting line (I-Connect007); the deal was expected to close in the second half of 2026 (Fabbaloo) |
Markforged generated roughly $70 million of 2025 revenue (that figure includes the binder jetting line Nano kept), so Stratasys is paying less than one year of revenue for the rest. Stratasys also bought assets of the resin startup Nexa3D, a pattern 3DPrint.com summarizes as the market shifting from startups to giants.
The investment lesson: buying several struggling hardware companies to create scale destroyed roughly $170 million of Nano Dimension shareholder value on Desktop Metal alone. Capital is now rewarding companies with demonstrated production demand, not breadth of technology.
Where demand is real: defense, metal, construction, and China
Defense and aerospace lead. Wohlers ranks defense first in revenue by sector. Stratasys says aerospace and defense, its largest vertical, grew 17% year on year in Q2. Divergent reported a fivefold revenue increase in 2025 and more than 200 new aerospace and defense part numbers in the first half, and lists General Atomics, Lockheed Martin, Raytheon and Triumph Group among its customers. VulcanForms said customer demand exceeded its production capacity for the first time.
Metal is the growth lane, and it is getting cheaper. Industry predictions in 3DPrint.com’s 2026 outlook center on metal moving from prototypes and low-rate production to full-rate production, with directed energy deposition growing for repair and production in aerospace, defense and energy. At the low end, a Mastrex dual-500W laser powder-bed machine launched at $185,000 (3D Printing Journal). 3D Systems says its semiconductor and high-performance-computing business grew almost 30% in Q2, mostly on manufactured metal parts.
Construction printing is now a defense and institutional product. Icon has built more than 270 homes and structures across five states and two countries, and the U.S. Army contracted it in January to print 10 barracks at Fort Bliss, Texas, for $62.8 million, which Icon calls the largest deployment of robotic construction technology in Department of Defense history (Construction Dive).
China is setting prices and going public. Creality listed in Hong Kong on May 29, 2026, Anycubic’s parent closed a Series B of hundreds of millions of yuan, UnionTech took a 120-machine bulk order and is investing RMB 150 million in a metal facility, and metal AM company Yuding finished IPO tutoring ahead of a likely STAR Market filing. DEVELOP3D’s assessment is that both Stratasys and Markforged lost ground to Chinese competitors while the Nano Dimension fight distracted them.
The practical reading for investors and operators: the durable revenue sits where a part has to be made domestically, quickly and in small to medium series, which describes most defense work. Consumer and prosumer hardware is a scale and price game dominated by Chinese manufacturers.
Bioprinting progress: tissue models now, implants next, organs later
Bioprinting today earns its revenue from research tools and drug-testing tissue models. Implantable tissues are in preclinical work and early human studies, and a full solid organ for transplant remains a long-term goal. A 2026 review in BioMed Engineering OnLine names skin grafts, cartilage replacements and vascularized tissue patches as the applications nearest translation.
| Application | Stage today | Main obstacle |
|---|---|---|
| Drug-testing tissue and tumor models | Commercial (for example CTIBIOTECH, Systemic Bio) | Throughput, reproducibility, pharma validation |
| Skin | Preclinical and clinical trials | Vascularization, multilayer complexity |
| Cartilage, soft tissue, muscle | Limited clinical use | Mechanical stability, structural integrity |
| Cardiac and vascular tissue | Preclinical models and functional prototypes | Synchronized beating, vessel integration |
| Kidney and urinary tissue | Drug screening and early preclinical | Filtration and multicellular organization |
| Whole solid organs (liver, kidney, lung, heart) | Federally funded research programs | Vascular networks, cell supply, scale |
The stage column for skin through kidney follows the application table in the PMC review.
Vascularization is still the wall. Without blood vessels, thick tissue cannot survive. Researchers are attacking it by inducing vessel growth after printing, by printing vascular channels directly, and by printing sacrificial scaffolds that dissolve to leave channels. A ScienceDirect review highlights faster platforms such as HITS-Bio and AI-enabled closed-loop manufacturing as steps toward clinical-scale tissue, alongside hybrid and decellularized-matrix bioinks and integration with organ-on-chip systems.
Translation is slow. One review states that fewer than 5% of laboratory innovations in the field have reached human trials (PMC). A Frontiers 2026 analysis of urogenital tissue engineering finds that none of the lab-proven bioprinting strategies there have reached clinical translation. Autologous grafts, such as PLATE grafts for vaginal atresia, have progressed under national regulatory interpretations because they use a patient’s own cells and well-characterized materials. The same paper notes that neither the FDA nor the EMA has issued dedicated guidelines for bioprinting in regenerative medicine, so how printing affects a product’s regulatory classification is still unclear. The authors argue the fastest clinical route is minimally manipulated autologous workflows.
Why it matters. ARPA-H cites about 120,000 people on U.S. organ waiting lists against about 45,000 transplants a year.
Market estimates are wide and mostly describe tools and models. Market Research Future values the 3D bioprinting market at $3.3 billion in 2025, growing 15.6% a year to $14.1 billion by 2035; Astute Analytica estimates $2.5 billion in 2025 and $15 billion by 2035. The narrower bioink segment is estimated by QYResearch at $224 million in 2025 and $734 million by 2032. These are vendor forecasts, and I could not verify their methodology.
Bioprinting capital: government moonshots, one pharma-backed platform, small seed bets
Bioprinting money is concentrated in three places: federal organ programs, a single pharma-partnered tissue-therapeutics company, and small rounds for implant and tissue-model startups. The tool makers that sold bioprinters to labs are restructuring.
| Who | What happened | Why it matters |
|---|---|---|
| ARPA-H PRINT program | Up to $176.8M over 5 years to build personalized, on-demand organs that do not need immunosuppressants; teams led by Carnegie Mellon, Wake Forest, the Wyss Institute and UC San Diego | Awards are contingent on hitting aggressive milestones; Carnegie Mellon aims for a liver ready for first-in-human trials in five years |
| Wake Forest (WFIRM) | Up to $24.8M over 5 years for on-demand bioprinted kidney tissue, with a commercialization plan; partners include PrintBio Inc. | Kidney tissue to augment renal function, not a full kidney |
| Aspect Biosystems | $115M Series B in January 2025; Novo Nordisk collaboration with $75M upfront and up to $650M in milestones per product, for diabetes and obesity | The category’s flagship pharma deal; PitchBook lists $211M raised in total (3DPrint.com says over $260M, so the totals differ by source) |
| Aspect, 2026 | A $79M Government of Canada investment announced in April, part of a $280M multi-year project; in January it also acquired cell-engineering technologies Novo stepped back from | Moves a Canadian company to the center of bioprinted tissue therapies |
| Cellbricks Therapeutics | EUR 10M seed in March 2026 led by Silicon Roundabout Ventures, with Germany’s SPRIND and ACT Venture Partners | Funds a lead adipose tissue implant and up to three preclinical animal studies; the company says its light-based printing is about 15x faster than other approaches (Tech.eu), which is its claim, not an independent finding |
| CTIBIOTECH | U.S. subsidiary in Philadelphia backed by nearly $27M of planned spending ($12M on operations over five years, $15M tied to IP); a EUR 1.25M Bpifrance grant for a cancer-testing platform | Operating commitment and grants, not a venture round; drug-testing tumor and skin models |
| VoxCell | $2.2M in SAFE notes, September 2026 | Human tissue models for drug development |
| 3D Systems with United Therapeutics | Long-running lung scaffold program; Systemic Bio was spun out in 2022 with $15M of seed funding and a goal of nearly $100M in annual revenue within five years | Orbital Economics calls the regenerative work pre-commercial inside a cash-constrained company |
| BICO (CELLINK) | Sold MatTek and Visikol to Sartorius for $80M; Q1 2025 revenue fell 17.3% to SEK 388.6M while bioprinting grew 41%; CELLINK cut about 20% of staff | The leading bioprinter seller is shrinking to profitability; its bioprinting line was its brightest spot |
For an investor, the pattern is that milestones, not revenue, set value. The things that would change the picture are a first-in-human result for a bioprinted tissue implant, the first PRINT milestone decisions, and a second large pharma partnership like Novo and Aspect.
Outlook: seven things to watch through 2027
The next year should show whether production demand can lift the whole industry or only a handful of defense-linked leaders.
- Stratasys closes Markforged. The deal was expected in the second half of 2026. Stratasys also told investors to expect a notable uptick in system sales in the second half, so Q3 and Q4 results test that claim.
- System sales versus services. Wohlers measured 3.6% system growth against 15.5% for services in 2025. A sustained rebound in machine orders would signal confidence is returning.
- Defense capacity. Watch whether VulcanForms, Divergent and Icon turn fresh capital into shipped volume, and whether Chinese metal players such as Yuding complete public listings.
- 3D Systems’ balance sheet and leadership. It raised $53.2 million of equity in Q2, holds $129 million of cash, guides to a small EBITDA loss in Q3, and announced a CEO succession plan.
- Nano Dimension’s strategic review. After selling or losing Desktop Metal and Markforged, its next move (it said Phase 3 is evaluating alternatives) could add another round of asset sales.
- Bioprinting milestones. First-in-human data for a bioprinted tissue implant, the first ARPA-H PRINT milestone decisions, and whether Cellbricks’ animal studies support a clinical filing.
- Regulation. Neither the FDA nor the EMA has published dedicated bioprinting guidance. A draft framework would be the biggest single de-risking event for the field.
This article is research, not investment advice. Market-size figures come from analyst summaries that I could read only in part, and private-company valuations rely on press reports.
Leave a Reply